The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective

Panobinostat is an oral pan-histone deacetylase inhibitor developed by Novartis. Panobinostat acts via epigenetic modification and inhibition of the aggresome pathway. In August 2015, the European Commission authorized panobinostat for use in combination with bortezomib and dexamethasone for the tre...

Descripción completa

Detalles Bibliográficos
Autores principales: San-Miguel, Jesus F., Einsele, Hermann, Moreau, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083773/
https://www.ncbi.nlm.nih.gov/pubmed/27677481
http://dx.doi.org/10.1007/s12325-016-0413-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083773/
https://www.ncbi.nlm.nih.gov/pubmed/27677481
http://dx.doi.org/10.1007/s12325-016-0413-7

Ejemplares similares